• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price

Clinical Trials in Heart Disease

A Companion to Braunwald's Heart Disease

9780721604084
564.48 zł
508.03 zł Save 56.45 zł Tax included
Lowest price within 30 days before promotion: 508.03 zł
Quantity
Product unavailable
Out of print

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Understanding clinical trials and the resulting outcomes is important to understanding the management of cardiovascular health. This new edition (a companion to Braunwalds Heart Disease) covers important new trials in cardiology therapies and prevention of cardiovascular problems. The world authorities on pharmacologic clinical trials write about the trials, the outcomes and importance for clinical practice.

This book gives the general cardiologist insight into the development of new therapies in cardiology as well as the process of how trials were used for those therapies. In addition to providing a manual for how to establish trials, trials for treatment and prevention are covered.

This book offers indispensable guidance for clinical decision-making in all patient care settings!
Product Details
Saunders
31391
9780721604084
9780721604084

Data sheet

Publication date
2004
Issue number
2
Cover
hard cover
Pages count
448
Dimensions (mm)
216 x 276
Weight (g)
1329
  • Section I. METHODOLOGY

    Chapter 1: Contributions of Basic Research, Observational Studies, and Randomized Trials
    Chapter 2: Methodology of Randomized Trials
    Chapter 3: Comparative Features of Primordial, Primary and Secondary Prevention Trials
    Chapter 4: Principles of Data and Safety Monitoring Boards in Randomized Trials

    Section II. TREATMENT TRIALS

    A. Treatment of Acute Coronary Ischemia

    Chapter 5: Aspirin and Thienopyridines
    Chapter 6: Heparin and Low Molecular Weight Heparin in Acute Coronary Ischemia
    Chapter 7: Clinical Trials in Thrombolytic Therapy
    Chapter 8: Clinical Trials of Direct Thrombin Inhibitors
    Chapter 9: Glycoprotein IIb/IIIa Receptor Inhibitors
    Chapter 10: Adjunctive Medical Therapy for Acute Myocardial Infarction
    Chapter 11: Primary, Rescue and Adjunctive Mechanical Intervention in the Setting of Acute Myocardial Infarction
    Chapter 12: Coronary Artery Bypass Surgery in Acute Coronary Syndromes

    B. Treatment of Arrhythmias

    Chapter 13: Drug Therapy for Ventricular Tachycardia and Ventricular Fibrillation
    Chapter 14: Antiarrhythmic Drug Therapy in Supraventricular Tachycardia
    Chapter 15: Anticoagulant and Antiplatelet Drug Therapy for Atrial Fibrillation
    Chapter 16: Clinical Trials in Arrhythmia Ablation
    Chapter 17: Clinical Trials of Implantable Cardioverter-Defibrillators (ICDs) and Cardiac Resynchronization Therapy/Defibrillation
    Chapter 18: Clinical Trials in Pacing

    C. Treatment of Congestive Heart Failure

    Chapter 19: Drugs Blocking the Renin-Angiotensin-Aldosterone System (RAAS)
    Chapter 20: Beta-blocker Treatment of Heart Failure
    Chapter 21: Clinical Trials in Heart Transplantation and Mechanical Cardiac Support for End-Stage Heart Failure

    Section III. PRIMARY AND SECONDARY PREVENTION TRIALS

    Chapter 22: Cholesterol Reduction
    Chapter 23: Blood Pressure Reduction Treatment Trials
    Chapter 24: Prevention Trials of Smoking Cessation
    Chapter 25: Physical Activity and Weight Loss
    Chapter 26: Aspirin, Other Antiplatelet Agents, and Anticoagulant Agents in the Secondary and Primary Prevention of Cardiovascular Disease
    Chapter 27: Postmenopausal Hormone Replacement Therapy
    Chapter 28: Antioxidant Vitamins
    Chapter 29: Dietary Factors
    Chapter 30: Cardiac Psychology/Behavioral Cardiology
    Chapter 31: Multiple Risk Factor Intervention Trials
    Chapter 32: Prevention Strategies: From the Office to the Community and Beyond
Comments (0)